查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1809911

IgA腎臟病市場（按藥物類別、治療方法、患者類型、最終用戶和分銷管道）—2025 年至 2030 年全球預測

IgA Nephropathy Market by Drug Class, Treatment, Patient Type, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

IgA腎臟病市場預計 2024 年將達到 13 億美元，2025 年將達到 13.7 億美元，2030 年將達到 18.5 億美元，複合年成長率為 6.10%。

主要市場統計數據
基準年2024年 13億美元
預計2025年 13.7億美元
預測年份 2030 18.5億美元
複合年成長率（%） 6.10%

IgA腎臟病，通常稱為伯傑氏病，是全球最常見的原發性腎絲球腎炎。含有免疫球蛋白A的免疫複合物沉積於腎系膜，引發連鎖發炎反應、系膜增生，最終導致腎絲球疤痕形成。這種異質性疾病的臨床頻譜廣泛，從無症狀性的鏡下血尿到迅速進展至末期腎病，對患者和醫療基礎設施帶來沉重負擔。

隨著我們理解的不斷加深，我們越來越清楚地認知到，早期診斷、分層風險評估和有針對性的治療性介入對於減緩疾病進展至關重要。目前的治療模式主要依賴血管收縮素轉化酵素抑制劑和血管收縮素受體阻斷劑來降低蛋白尿，並在​​高風險病例中輔以免疫抑制劑。然而，儘管採取了這些措施，仍存在未滿足的需求，包括實現持久緩解、最大限度地減少副作用以及根據患者個別情況制定治療方案。

IgA腎臟病的全球盛行率存在地域差異，亞洲人群的發生率高於西方人群。這種差異凸顯了全面臨床試驗設計的必要性，以及針對不同地區制定治療可近性和報銷方案的重要性。此外，新興的生物標記研究和基因組分析的進展凸顯了個人化醫療的發展方向，並有望最佳化患者選擇並改善療效。

本執行摘要整合了最新的臨床數據、技術創新和影響IgA腎臟病格局的監管格局，旨在應對這些複雜問題。透過嚴謹的分析，我們得以洞察不斷發展的治療方法、診斷進展和相關人員的動態，從而幫助決策者把握機會，最佳化策略舉措。

診斷的進步和治療方法的革命性變化正在重新定義 IgA腎臟病的治療前景和研究軌跡

近年來，由於診斷準確性的提高和治療方法的創新，IgA腎臟病的現狀發生了顯著變化。以往，臨床醫生依靠侵入性腎臟切片檢查來確認疾病活動，而現在他們能夠獲得新的生物標記物，例如血清半乳糖缺乏切片檢查IgA1 濃度和尿液細胞激素激素譜。這些工具有助於更早實施更個人化的干涉措施，從而可能重塑患者分層並改善長期療效。

評估2025年美國關稅調整對全球供應鏈、藥品價格和IgA腎臟病治療可及性的深遠影響

美國計劃於2025年宣布新的關稅，將對全球醫藥供應鏈造成重大干擾。來自主要製造地的活性藥物原料藥可能面臨進口關稅上調，這將對生產成本產生連鎖反應，並最終影響藥品價格。鑑於腎臟病治療藥物的淨利率已受到嚴格審查，這些調整可能會降低盈利並限制患者的用藥管道。

對 IgA腎臟病治療動態的策略性洞察，涵蓋藥物類別、治療方案、患者類型、最終用戶和分銷管道

多層次細分分析揭示了IgA腎臟病市場多樣化的治療和護理動態。依藥物類別分類，血管張力素轉換酶（ACE）抑制劑和血管收縮素受體阻斷劑與免疫抑制劑（例如Azathioprine、皮質類固醇、Cyclophosphamide和Mycophenolate Mofetil）並存。單株抗體處於領先地位，致力於提供針對潛在免疫病理的標靶作用機制。

IgA腎臟病治療生態系的地區差異凸顯了醫療保健基礎設施、獲取機制和採用模式的差異

IgA腎臟病治療的地區差異反映了醫療基礎設施、報銷框架和治療方法採用模式的差異。在美洲，強大的透析網路和先進的移植項目得到了結構化保險體系的支持，這些體係有助於患者獲得成熟和新興的治療方法。電子健康記錄與基於價值的合約舉措的整合進一步簡化了護理協調和療效衡量。

大型製藥企業的策略性舉措和競爭地位塑造了 IgA腎臟病治療創新的未來

大型製藥和生技公司正在積極調整其投資組合，以抓住IgA腎臟病領域的機會。現有的全球性公司正在利用其免疫學專業知識來推進單株抗體候選藥物研發，並經常透過策略性收購和授權協議來補充其內部研發管線。對早期研究合作的投資凸顯了他們致力於發現新標靶和加速轉化研究的決心。

為行業領導者提供主動策略和戰術性建議，以利用 IgA腎臟病藥物開發的發展趨勢

為了充分利用IgA腎臟病領域不斷發展的機遇，業界領導者應優先投資精準診斷和生物標記檢驗，以加強患者選擇和治療監測。建立整合臨床、監管和商業專業知識的跨職能團隊，可以簡化研發週期並最佳化資源配置。

結合專家訪談、二次研究和數據三角測量的綜合方法，為 IgA腎臟病市場的動態提供了可靠的見解

該分析以一套嚴謹的方法論為基礎，該方法論整合了對關鍵意見領袖、臨床專家和市場相關人員進行深入訪談所獲得的定性見解。二次研究則有系統地查閱了同行評審期刊、臨床試驗註冊中心、監管備案文件和公開的企業資料，從而構建了全面的資訊庫。

主要研究結果綜合強調了協作創新和策略合作的迫切性，以推動 IgA腎臟病的治療發展

本執行摘要中提出的證據凸顯了IgA腎臟病管理中協作創新的迫切性。精準診斷、標靶免疫療法和數位健康平台的出現，相關人員提供了前所未有的工具，以重新定義患者照護並改善長期腎臟預後。然而，要實現這一潛力，需要齊心協力，縮小可及性差距，簡化臨床開發流程，並協調整個醫療生態系統的獎勵。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 標靶補體抑制劑在治療領域的快速引入
  • 擴大非侵入性生物標記診斷將改變患者管理
  • 透過整合人工智慧驅動的影像平台增強疾病監測
  • 個人化治療流程的出現，可以最佳化高風險患者的治療結果
  • 監管部門對新型生技藥品的推動塑造了治療格局
  • 戰略夥伴關係加速口服非類固醇藥物的開發
  • 不斷發展的報銷模式支持 IgA腎臟病護理途徑的早期療育
  • IgA腎臟病治療臨床試驗中病患報告結果的重要性日益增加

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

8. IgA腎臟病市場（依藥物類別）

  • 血管緊張素轉換酶抑制劑
  • 血管收縮素素受體阻斷劑
  • 免疫抑制劑
    • Azathioprine
    • 皮質類固醇
    • Cyclophosphamide
    • Mycophenolate Mofetil
  • 單株抗體

9. IgA腎臟病市場（依治療）

  • 透析
  • 免疫抑制治療
  • 腎臟移植
  • 非免疫抑制治療
  • 血漿置換

第 10 章 IgA腎臟病市場（依患者類型）

  • 成人
  • 老年患者
  • 兒科患者

第 11 章 IgA腎臟病市場（按最終用戶）

  • 家庭醫療保健
  • 醫院
  • 研究機構
  • 專科診所

第 12 章 IgA腎臟病市場（按分銷管道）

  • 線下藥局
    • 醫院藥房
    • 零售藥局
  • 網路藥局

13.美洲IgA腎臟病市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14. 歐洲、中東和非洲IgA腎臟病市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

15. 亞太地區IgA腎臟病變市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第16章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Alnylam Pharmaceuticals, Inc.
    • Apellis Pharmaceuticals Inc.
    • Biogen Inc.
    • Boehringer Ingelheim International GmbH.
    • Calliditas Therapeutics AB by Asahi Kasei Corporation
    • ChemoCentryx, Inc. by Amgen Inc.
    • Eledon Pharmaceuticals Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • Ionis Pharmaceuticals Inc
    • Keymed Biosciences Inc.
    • Novartis AG
    • NovelMed Inc.
    • Novo Nordisk A/S.
    • Omeros Corporation
    • Otsuka Pharmaceutical Co. Ltd
    • Q32 Bio Inc.
    • Takeda Pharmaceutical Company
    • Travere Therapeutics Inc
    • Vera Therapeutics Inc
    • Vertex Pharmaceuticals Incorporated

第17章 研究人工智慧

第18章 研究統計

第19章 研究聯絡人

第20章 研究報導

第21章 附錄

Product Code: MRR-3E7318E83176

The IgA Nephropathy Market was valued at USD 1.30 billion in 2024 and is projected to grow to USD 1.37 billion in 2025, with a CAGR of 6.10%, reaching USD 1.85 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.30 billion
Estimated Year [2025] USD 1.37 billion
Forecast Year [2030] USD 1.85 billion
CAGR (%) 6.10%

IgA nephropathy, commonly referred to as Berger's disease, is the most prevalent form of primary glomerulonephritis worldwide. It results from the deposition of immunoglobulin A-containing immune complexes in the renal mesangium, triggering a cascade of inflammation, mesangial proliferation, and eventual glomerular scarring. This heterogenous disease manifests a broad clinical spectrum, ranging from asymptomatic microscopic hematuria to rapid progression toward end-stage renal disease, placing immense strain on patients and healthcare infrastructures alike.

As our understanding deepens, it has become apparent that early diagnosis, stratified risk assessment, and targeted therapeutic interventions are critical to delaying disease progression. Current treatment paradigms rely heavily on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers to mitigate proteinuria, supplemented by immunosuppressive agents for high-risk cases. Yet, despite these measures, unmet needs persist in achieving sustained remission, minimizing adverse effects, and tailoring regimens to individual patient profiles.

The global prevalence of IgA nephropathy has shown geographic variability, with higher incidence observed in Asian populations compared to Western cohorts. This divergence underscores the importance of region-specific approaches to treatment access and reimbursement, as well as the need for inclusive clinical trial designs. Moreover, emerging biomarker research and advances in genomic profiling highlight the trajectory toward personalized medicine, promising to refine patient selection and improve outcomes.

To address these complexities, this executive summary synthesizes the latest clinical data, technological innovations, and regulatory developments shaping the IgA nephropathy landscape. Through rigorous analysis, critical insights emerge on evolving therapeutic approaches, diagnostic enhancements, and stakeholder dynamics, enabling decision-makers to navigate opportunities and optimize strategic initiatives.

Revolutionary Shifts in Diagnostic Advancements and Therapeutic Modalities Redefine the IgA Nephropathy Treatment Landscape and Research Trajectory

Recent years have witnessed a profound transformation in the IgA nephropathy landscape, driven by advances in diagnostic precision and therapeutic innovation. Once reliant on invasive renal biopsies to confirm disease activity, clinicians now have access to novel biomarkers such as serum galactose-deficient IgA1 concentrations and urinary cytokine profiles. These tools are reshaping patient stratification and enabling earlier, more personalized interventions that have the potential to improve long-term outcomes.

Simultaneously, the therapeutic paradigm is shifting toward targeted immunomodulation. Following the success of monoclonal antibodies in other autoimmune conditions, several pipeline candidates are advancing into late-stage clinical development. These agents aim to interrupt key pathways in IgA-mediated inflammation, offering the promise of disease modification beyond conventional corticosteroids and cytotoxic agents. Such targeted approaches are complemented by next-generation immunosuppressants that seek to balance efficacy with a reduced adverse-event profile.

Digital health solutions are also emerging as a critical component of patient management. Remote monitoring platforms, artificial intelligence-driven imaging analytics, and telemedicine support integrated care pathways that empower patients and streamline clinical workflows. Furthermore, collaborative frameworks among payors, providers, and patient advocacy groups are accelerating access models for innovative treatments.

As these developments converge, the IgA nephropathy landscape is poised for a new era of precision medicine. Stakeholders who embrace these transformative shifts will be well positioned to deliver enhanced patient outcomes, optimize resource allocation, and capture value in this dynamic field.

Evaluating the Far-Reaching Consequences of United States 2025 Tariff Adjustments on Global Supply Chains, Drug Pricing, and Access to IgA Nephropathy Treatments

The announcement of new United States tariff measures scheduled for 2025 introduces a pivotal disruptor to global pharmaceutical supply chains. Active pharmaceutical ingredients sourced from leading manufacturing hubs may face increased import duties, cascading through production costs and influencing final drug pricing. For therapies addressing IgA nephropathy, where margins are already under scrutiny, these adjustments threaten to erode profitability and impose constraints on patient access.

Manufacturers are evaluating mitigation strategies, including geographic diversification of API sourcing and onshore capacity expansion. However, these initiatives require significant capital investment and extended timelines, potentially delaying the commercialization of emerging monoclonal antibodies and novel immunosuppressants. Pharmaceutical distributors and wholesalers must also navigate revised logistics expenses, which could lead to altered contract terms with providers and payors.

Payor organizations are anticipated to intensify formulary management and reimbursement assessments in light of cost pressures. They may negotiate more aggressive pricing concessions or increase utilization controls, further impacting therapy uptake. In parallel, regulatory agencies are exploring mechanisms to offset tariff impacts, such as expedited review pathways and targeted subsidies for critical drug classes.

In this context, industry participants must adopt a proactive stance to assess the cumulative financial and operational effects of these tariff measures. Scenario planning, stakeholder collaboration, and policy advocacy will be essential to safeguard both commercial interests and patient access to life-altering IgA nephropathy treatments.

Strategic Insights into IgA Nephropathy Care Dynamics Spanning Drug Classes, Treatment Options, Patient Types, End Users, and Distribution Channels

A multifaceted segmentation analysis illuminates the diverse therapeutic and care dynamics within the IgA nephropathy market. In the domain of drug classes, the foundational reliance on ACE inhibitors and angiotensin receptor blockers continues to coexist with immunosuppressants such as azathioprine, corticosteroids, cyclophosphamide, and mycophenolate mofetil. At the frontier, monoclonal antibodies endeavor to offer targeted mechanisms of action that address underlying immunopathology.

Treatment modalities display significant heterogeneity, spanning chronic dialysis, immunosuppressive therapy protocols, kidney transplant interventions, non-immunosuppressive supportive therapies, and plasmapheresis procedures. Each treatment corridor presents distinct efficacy profiles, resource requirements, and patient tolerance considerations.

Patient demographics further shape demand patterns, with adult populations constituting the majority of cases, while elderly and pediatric patients require tailored approaches to dosing, comorbidity management, and safety monitoring. End-user settings reflect a wide distribution of care delivery, encompassing home healthcare programs, hospital inpatient and outpatient units, dedicated research institutes, and specialized nephrology clinics that are optimizing care coordination.

Distribution channels influence accessibility and patient engagement, with offline pharmacies-comprising both hospital-based dispensaries and retail outlets-remaining the primary access point for most therapies, complemented by growing adoption of online pharmacy services. This comprehensive segmentation perspective underscores the necessity for strategic alignment of product portfolios, service delivery models, and market access planning to address the full spectrum of stakeholder needs.

Regional Disparities in IgA Nephropathy Treatment Ecosystems Highlight Differing Healthcare Infrastructure, Access Mechanisms and Adoption Patterns

Regional dynamics in the IgA nephropathy arena reveal divergent patterns in healthcare infrastructure, reimbursement frameworks, and treatment adoption. In the Americas, robust dialysis networks and advanced transplant programs are supported by structured insurance systems that facilitate patient access to established and emerging therapies. Integration of electronic health records and value-based contracting initiatives further streamlines care coordination and outcome measurement.

Within Europe, the Middle East, and Africa, public health systems vary widely, driving disparities in the availability of high-cost interventions. Some European nations have embraced health technology assessments to inform coverage decisions for novel agents, while certain Middle Eastern and African markets remain constrained by budgetary limitations and limited local production of biologics.

Asia-Pacific markets are characterized by rapid growth in disease awareness and expanding clinical trial activity, especially in East Asian countries with historically elevated incidence rates. Reimbursement policies are evolving to accommodate breakthrough therapies, though out-of-pocket expenses and regulatory heterogeneity pose challenges. In emerging economies, partnerships between local stakeholders and multinational companies are instrumental in fostering infrastructure development, knowledge transfer, and patient education programs.

These regional insights underscore the importance of customized market entry strategies and stakeholder engagement plans that address the unique policy landscapes, funding mechanisms, and care pathways in each geography.

Strategic Movements and Competitive Positioning of Leading Pharmaceutical and Biotech Entities Shaping the Future of IgA Nephropathy Treatment Innovations

Leading pharmaceutical and biotechnology companies are actively reconfiguring their portfolios to capture opportunities in the IgA nephropathy space. Established global players are leveraging their immunology expertise to advance monoclonal antibody candidates, often through strategic acquisitions or licensing agreements that supplement internal pipelines. Investment in early-phase research collaborations underscores a commitment to identifying novel targets and expediting translational studies.

Specialized biotech firms are positioning themselves as pioneers in precision nephrology, focusing on biomarkers and companion diagnostics to support differentiated clinical development programs. These organizations often engage academic partners to enhance trial design and access to patient cohorts, thereby de-risking clinical pathways and enriching data quality.

Competitive positioning is further influenced by regulatory milestones and orphan drug designations, which provide incentives such as market exclusivity and expedited review. Companies with global manufacturing footprints are optimizing supply chains to ensure seamless product availability across multiple regions, while those with virtual or consortium models emphasize flexibility and cost efficiency.

Collaborative alliances between industry, academic centers, and patient advocacy groups are accelerating knowledge exchange and facilitating real-world evidence generation. As these entities refine go-to-market strategies, differentiation will hinge on the integration of therapeutic efficacy, safety profiles, and holistic patient support services.

Proactive Strategies and Tactical Recommendations Empowering Industry Leaders to Capitalize on Evolving Trends in IgA Nephropathy Therapeutic Development

To capitalize on the evolving IgA nephropathy landscape, industry leaders should prioritize investment in precision diagnostics and biomarker validation to enhance patient selection and treatment monitoring. Establishing cross-functional teams that integrate clinical, regulatory, and commercial expertise will streamline development lifecycles and optimize resource allocation.

Engagement with payors early in the clinical development process is essential to define value propositions and negotiate innovative contracting models that align pricing with outcomes. Simultaneously, fostering partnerships with patient advocacy organizations can strengthen trial recruitment, amplify real-world data initiatives, and support adherence programs that improve long-term patient retention.

Diversifying supply chain footprints, including nearshoring and dual-sourcing APIs, will mitigate tariff-related risks and ensure continuity of supply. Companies should also explore digital health platforms for remote patient monitoring and telemedicine services that enhance access and reduce the burden on healthcare facilities.

Finally, fostering an agile organizational culture that embraces data analytics, cross-industry collaboration, and rapid iteration will position businesses to respond effectively to regulatory shifts, competitive pressures, and evolving patient needs. By adopting these proactive strategies, stakeholders can drive meaningful innovation, capture market opportunities, and deliver superior outcomes for individuals living with IgA nephropathy.

Comprehensive Methodology Combining Expert Interviews, Secondary Research, and Data Triangulation to Deliver Robust Insights into IgA Nephropathy Market Dynamics

This analysis is underpinned by a robust methodology that integrates qualitative insights from in-depth interviews with key opinion leaders, clinical experts, and market stakeholders. Secondary research encompassed a systematic review of peer-reviewed journals, clinical trial registries, regulatory filings, and publicly available corporate disclosures to construct a comprehensive intelligence base.

Data triangulation techniques were employed to reconcile disparate information sources, ensuring the veracity of clinical endpoints, regulatory developments, and strategic initiatives. Market dynamics were further validated through cross-comparison of regional reimbursement policies, treatment guidelines, and real-world evidence from healthcare databases.

An expert advisory panel provided ongoing validation of emerging trends and potential market disruptors, guiding scenario planning and sensitivity analyses. This collaborative approach facilitated the refinement of key assumptions and enabled the identification of high-impact opportunities across the IgA nephropathy continuum.

By combining rigorous secondary research, expert validation, and methodical data integration, this study delivers actionable insights that reflect the complexity of the IgA nephropathy ecosystem and support informed decision-making.

Synthesis of Key Findings Underscoring the Urgency for Collaborative Innovation and Strategic Alignment to Advance IgA Nephropathy Therapeutic Development

The collective evidence presented in this executive summary underscores the urgency for collaborative innovation in IgA nephropathy management. With the advent of precision diagnostics, targeted immunotherapies, and digital health platforms, stakeholders have unprecedented tools to redefine patient care and improve long-term renal outcomes. However, realizing this potential will require concerted efforts to bridge gaps in access, streamline clinical development, and align incentives across the healthcare ecosystem.

Tariff-related challenges, evolving reimbursement landscapes, and regional disparities further emphasize the need for adaptive strategies that address both commercial viability and patient-centric objectives. Companies must embrace agile operating models, engage proactively with regulatory and payor authorities, and invest in infrastructure that supports decentralized care and real-world evidence generation.

Ultimately, the future of IgA nephropathy therapeutics will be shaped by those who can integrate scientific innovation with market realities, forging partnerships that accelerate translation from bench to bedside. As the landscape continues to evolve, the insights contained herein offer a strategic foundation for decision-makers committed to advancing therapies that alleviate disease burden and enhance quality of life for patients worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Rapid adoption of targeted complement inhibitors in IgA nephropathy therapy pipelines
  • 5.2. Expansion of noninvasive biomarker diagnostics transforming IgA nephropathy patient management
  • 5.3. Integration of AI-driven imaging platforms enhancing IgA nephropathy disease monitoring
  • 5.4. Emergence of personalized treatment algorithms optimizing outcomes for high-risk IgA nephropathy patients
  • 5.5. Regulatory momentum for novel biologics shaping IgA nephropathy therapeutic landscape
  • 5.6. Strategic partnerships accelerating development of oral nonsteroidal agents in IgA nephropathy
  • 5.7. Evolving reimbursement models supporting early intervention in IgA nephropathy care pathways
  • 5.8. Growing emphasis on patient-reported outcomes in clinical trials for IgA nephropathy treatments

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. IgA Nephropathy Market, by Drug Class

  • 8.1. Introduction
  • 8.2. ACE Inhibitors
  • 8.3. Angiotensin Receptor Blockers
  • 8.4. Immunosuppressants
    • 8.4.1. Azathioprine
    • 8.4.2. Corticosteroids
    • 8.4.3. Cyclophosphamide
    • 8.4.4. Mycophenolate mofetil
  • 8.5. Monoclonal Antibodies

9. IgA Nephropathy Market, by Treatment

  • 9.1. Introduction
  • 9.2. Dialysis
  • 9.3. Immunosuppressive Therapy
  • 9.4. Kidney Transplant
  • 9.5. Non-Immunosuppressive Therapy
  • 9.6. Plasmapheresis

10. IgA Nephropathy Market, by Patient Type

  • 10.1. Introduction
  • 10.2. Adults
  • 10.3. Elderly Patients
  • 10.4. Pediatric Patients

11. IgA Nephropathy Market, by End User

  • 11.1. Introduction
  • 11.2. Home Healthcare
  • 11.3. Hospitals
  • 11.4. Research Institutes
  • 11.5. Specialty Clinics

12. IgA Nephropathy Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Offline Pharmacies
    • 12.2.1. Hospital Pharmacies
    • 12.2.2. Retail Pharmacies
  • 12.3. Online Pharmacies

13. Americas IgA Nephropathy Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa IgA Nephropathy Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific IgA Nephropathy Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Alnylam Pharmaceuticals, Inc.
    • 16.3.2. Apellis Pharmaceuticals Inc.
    • 16.3.3. Biogen Inc.
    • 16.3.4. Boehringer Ingelheim International GmbH.
    • 16.3.5. Calliditas Therapeutics AB by Asahi Kasei Corporation
    • 16.3.6. ChemoCentryx, Inc. by Amgen Inc.
    • 16.3.7. Eledon Pharmaceuticals Inc.
    • 16.3.8. Eli Lilly and Company
    • 16.3.9. F. Hoffmann-La Roche Ltd
    • 16.3.10. Ionis Pharmaceuticals Inc
    • 16.3.11. Keymed Biosciences Inc.
    • 16.3.12. Novartis AG
    • 16.3.13. NovelMed Inc.
    • 16.3.14. Novo Nordisk A/S.
    • 16.3.15. Omeros Corporation
    • 16.3.16. Otsuka Pharmaceutical Co. Ltd
    • 16.3.17. Q32 Bio Inc.
    • 16.3.18. Takeda Pharmaceutical Company
    • 16.3.19. Travere Therapeutics Inc
    • 16.3.20. Vera Therapeutics Inc
    • 16.3.21. Vertex Pharmaceuticals Incorporated

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. IGA NEPHROPATHY MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL IGA NEPHROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. IGA NEPHROPATHY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. IGA NEPHROPATHY MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. IGA NEPHROPATHY MARKET: RESEARCHAI
  • FIGURE 26. IGA NEPHROPATHY MARKET: RESEARCHSTATISTICS
  • FIGURE 27. IGA NEPHROPATHY MARKET: RESEARCHCONTACTS
  • FIGURE 28. IGA NEPHROPATHY MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. IGA NEPHROPATHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL IGA NEPHROPATHY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL IGA NEPHROPATHY MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DIALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DIALYSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSIVE THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY KIDNEY TRANSPLANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY KIDNEY TRANSPLANT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY NON-IMMUNOSUPPRESSIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY NON-IMMUNOSUPPRESSIVE THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY PLASMAPHERESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY PLASMAPHERESIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ADULTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ELDERLY PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ELDERLY PATIENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 72. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 73. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 74. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 75. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 77. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 79. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 80. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 81. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 82. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 83. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 84. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 85. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 87. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 88. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 89. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 90. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 91. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 92. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 93. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 94. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 95. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 96. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 97. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 98. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 99. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 100. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 101. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 102. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 103. CANADA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 104. CANADA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 105. CANADA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 106. CANADA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 107. CANADA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 108. CANADA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 109. CANADA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 110. CANADA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 111. CANADA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 112. CANADA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 113. CANADA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. CANADA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 115. CANADA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 116. CANADA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 117. MEXICO IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 118. MEXICO IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 119. MEXICO IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 120. MEXICO IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 121. MEXICO IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 122. MEXICO IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 123. MEXICO IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. MEXICO IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 125. MEXICO IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 126. MEXICO IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 127. MEXICO IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 128. MEXICO IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 129. MEXICO IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 130. MEXICO IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 131. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 132. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 133. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 134. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 135. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 136. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 137. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 139. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 140. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 141. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 143. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 144. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 145. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 146. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 147. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 148. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 149. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 150. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 151. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 153. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 155. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 156. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 157. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 158. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 175. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 176. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 177. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 178. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 179. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 180. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 181. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 183. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 186. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 188. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 189. GERMANY IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 190. GERMANY IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 191. GERMANY IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 192. GERMANY IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 193. GERMANY IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 194. GERMANY IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 195. GERMANY IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. GERMANY IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 197. GERMANY IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. GERMANY IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 199. GERMANY IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 200. GERMANY IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 201. GERMANY IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 202. GERMANY IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 203. FRANCE IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 204. FRANCE IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 205. FRANCE IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 206. FRANCE IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 207. FRANCE IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 208. FRANCE IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 209. FRANCE IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. FRANCE IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 211. FRANCE IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. FRANCE IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 213. FRANCE IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. FRANCE IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 215. FRANCE IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 216. FRANCE IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 217. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 218. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 219. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 220. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 221. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 222. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 223. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 225. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 227. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 229. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 230. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 231. ITALY IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 232. ITALY IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 233. ITALY IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 234. ITALY IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 235. ITALY IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 236. ITALY IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 237. ITALY IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. ITALY IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. ITALY IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. ITALY IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 241. ITALY IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 242. ITALY IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 243. ITALY IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 244. ITALY IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 245. SPAIN IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 246. SPAIN IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 247. SPAIN IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 248. SPAIN IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 249. SPAIN IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 250. SPAIN IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 251. SPAIN IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. SPAIN IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 253. SPAIN IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. SPAIN IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 255. SPAIN IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. SPAIN IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 257. SPAIN IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 258. SPAIN IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 259. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 260. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 261. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 262. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 263. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 264. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 265. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 274. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 276. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 278. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 279. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 281. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 283. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 285. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 286. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 287. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 288. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 289. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 290. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 291. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 292. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 293. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 295. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 297. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 299. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 300. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 301. DENMARK IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 302. DENMARK IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 303. DENMARK IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 304. DENMARK IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 305. DENMARK IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 306. DENMARK IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 307. DENMARK IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. DENMARK IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 309. DENMARK IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. DENMARK IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 311. DENMARK IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. DENMARK IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 313. DENMARK IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 314. DENMARK IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 315. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 316. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 317. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 318. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 319. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 320. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 321. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 323. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 325. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 326. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 328. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 329. QATAR IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 330. QATAR IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 331. QATAR IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 332. QATAR IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 333. QATAR IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 334. QATAR IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 335. QATAR IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. QATAR IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 337. QATAR IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 338. QATAR IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 339. QATAR IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 340. QATAR IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 341. QATAR IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 342. QATAR IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 343. FINLAND IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 344. FINLAND IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 345. FINLAND IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 346. FINLAND IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 347. FINLAND IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 348. FINLAND IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 349. FINLAND IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 350. FINLAND IG